Compound
coenzyme Q10
Pinned: ChEBI labels the entry by its common name, so the systematic form missed. Ubiquinol is the reduced form and a separate node if a trial doses it — products sell both and they are not interchangeable.
Studied for
12 endpoints, 13 findings, from 4 papers — 12 of them found no effect.
- Total antioxidant capacityno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- All-cause mortalityno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- C-reactive protein concentrationno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Erythrocyte sedimentation rateno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
- Intensive care unit length of stayno detected effectGrade A, Well established. Replicated human trial evidence, consistent direction.
Structure
- Class
- Organic compound
- Formula
- C59H90O4
- Mass
- 863.365 g/mol
- Charge
- 0
- InChIKey
- ACTIUHUUMQJHFO-UPTCCGCDSA-N
- SMILES
- COC1=C(OC)C(=O)C(C/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CC/C=C(C)CCC=C(C)C)=C(C)C1=O
- Look it up
- ChEBIBy InChIKey
Identity from ChEBI. Not evidence — none of it carries a grade.
What the evidence says
How to read these marks13 findings across 12 endpoints, from 4 papers, strongest first, 12 of them null.
What moved
1 finding
Decreases fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The administration of CoQ10 resulted in a significant decrease in FBG levels (ESWMD = −5.04, 95% CI: −7.67, −2.40; p < 0.001, I 2 = 58.7%, p = 0.04) (Figure.”
Quoted verbatim from Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.. - Study
- meta-analysis
- Dose
- 110 to 376.6 mg/day CoQ10 across the included meta-analyses
- Population
- Adults with type 2 diabetes, obesity, polycystic ovary syndrome, chronic kidney disease, metabolic syndrome and other cardiometabolic conditions, from the randomised controlled trials pooled by eight meta-analyses.
Effect -5.04 mean difference, 95% CI -7.67 to -2.4
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.2026PMID:41859772
What did not
12 findings
Measured, and no effect detected. These are findings, not gaps — a trial that looked and found nothing is the most easily lost result in this field.
No detected effect on all-cause mortality
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“Moreover, no significant difference was observed in the 28-day mortality rate between the two groups (2 in the CoQ10 group vs. 3 in the placebo group) (P = 0.99).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on C-reactive protein concentration
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The differences in the CRP and ESR levels were not significant between CoQ10 and placebo groups (P = 0.550 and P = 0.306, respectively) (Table 2).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on erythrocyte sedimentation rate
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“The differences in the CRP and ESR levels were not significant between CoQ10 and placebo groups (P = 0.550 and P = 0.306, respectively) (Table 2).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on malondialdehyde (circulating)
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“As shown in Table 2, the between-group comparison revealed no significant difference between CoQ10 and placebo groups at the end of the study for MDA (P = 0.692), SOD activity (P = 0.633), and TAC (P = 0.865).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on superoxide dismutase activity
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“As shown in Table 2, the between-group comparison revealed no significant difference between CoQ10 and placebo groups at the end of the study for MDA (P = 0.692), SOD activity (P = 0.633), and TAC (P = 0.865).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on total antioxidant capacity
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull resultreplicated ×1“As shown in Table 2, the between-group comparison revealed no significant difference between CoQ10 and placebo groups at the end of the study for MDA (P = 0.692), SOD activity (P = 0.633), and TAC (P = 0.865).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
Show the remaining 6
No detected effect on intensive care unit length of stay
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull result“ICU length of stay in the CoQ10 group (18.83 ± 10.72) was shorter than the placebo group (23.60 ± 10.03); however, the difference was not statistically significant (P = 0.122).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on clinical pregnancy rate
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“No noticeable variations were demonstrated in clinical pregnancy rates (P = 0.888), lower miscarriage rates (p = 0.676), or twin pregnancies (p = 0.792); however, CoQ10 appeared to demonstrate promising outcomes (Table 3).”
Quoted verbatim from Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.. - Study
- RCT
- Dose
- Coenzyme Q10 200 mg twice daily (Synapse CoQ10 200 mg, Synapse Pharm), started one month before the ICSI cycle and continued through it
- Population
- Women aged 25 to 45 with poor ovarian response by the Bologna criteria undergoing intracytoplasmic sperm injection; secondary endpoint.
No detected effect on blood haemoglobin concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“As shown in Table 2, there were no significant differences in hematological parameters (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, lymphocyte, neutrophil, and platelet) between CoQ10 and placebo groups at the end of the study (P > 0.05).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on haematocrit
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“As shown in Table 2, there were no significant differences in hematological parameters (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, lymphocyte, neutrophil, and platelet) between CoQ10 and placebo groups at the end of the study (P > 0.05).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on total leukocyte count
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“As shown in Table 2, there were no significant differences in hematological parameters (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, lymphocyte, neutrophil, and platelet) between CoQ10 and placebo groups at the end of the study (P > 0.05).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.. - Study
- RCT
- Participants
- 52
- Duration
- 10 days
- Dose
- 100 mg three times a day after meals, total 300 mg/day
- Population
- Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; primary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600
No detected effect on total antioxidant capacity
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×1“There was no statistically significant change in TAC between the patients treated with doxorubicin + CoQ10 and doxorubicin + placebo.”
Quoted verbatim from Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.. - Study
- crossover
- Participants
- 6
- Dose
- 300 mg/day, two 150 mg softgel capsules once daily with food
- Population
- Women aged 21 or older with stage I-III breast cancer receiving dose-dense doxorubicin plus cyclophosphamide, each acting as her own control across one cycle with coenzyme Q10 and one with placebo; secondary endpoint.
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.2025PMID:41261512
What it touches on the way
A finding says coenzyme Q10 moved an endpoint. This is the biology in between: the proteins and reactions it runs through to get there. It is where to look for the two things a list of findings cannot answer — why a result might happen, and what else acts on the same machinery.
4 of these are proteins with a page of their own, and that is the door: a protein page says what else it carries, which is how one compound leads to the next.
Mechanistic reach
4 entities
4 entities reached, most connected first. Hub metabolites are excluded, so this is not a claim that the compound touches everything.
0 reported hop4 assembled from the scaffold
Where it reaches
10 systems, 24 regions, 175 tissues, 175 transporter routes.
Loading the model…